BDBM359496 4-(1-(2,6-dichlorobenzoyl)- 4,5,6,7-tetrahydro-1H-indazol- 3-yl)benzoic acid::US10221142, Example 1M
SMILES: OC(=O)c1ccc(cc1)-c1nn(C(=O)c2c(Cl)cccc2Cl)c2CCCCc12
InChI Key: InChIKey=XMEYOVRZIYHHRR-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nuclear receptor ROR-gamma (Homo sapiens (Human)) | BDBM359496![]() (4-(1-(2,6-dichlorobenzoyl)- 4,5,6,7-tetrahydro-1H-...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 13.9 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Sharp & Dohme Corp. US Patent | Assay Description The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I... | US Patent US10221142 (2019) BindingDB Entry DOI: 10.7270/Q2M90BZ0 | |||||||||||
More data for this Ligand-Target Pair |